Targeting N-acetyl-L-aspartate transport to improve outcomes in Canavan disease
Manipulating N-acetyl-L-aspartate transport to treat Canavan leukodystrophy
This study is exploring a new way to help people with Canavan disease by trying to lower a substance in the brain that causes problems, with the hope of improving movement and brain function.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10554428 on NIH RePORTER |
What this research studies
This research focuses on Canavan disease, a genetic disorder that affects brain function due to a deficiency in the enzyme aspartoacylase. The study aims to manipulate the transport of N-acetyl-L-aspartate (NAA) in the brain to reduce its elevated levels, which are linked to neurological deficits. By using innovative techniques such as antisense oligonucleotides to inhibit the enzyme responsible for NAA synthesis, the researchers hope to reverse motor deficits and brain damage in affected individuals. This approach has shown promise in animal models, suggesting potential benefits for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are infants and children diagnosed with Canavan disease who are experiencing neurological deficits.
Not a fit: Patients with other forms of leukodystrophy or those without a diagnosis of Canavan disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve neurological function and quality of life for patients with Canavan disease.
How similar studies have performed: Previous studies have shown success in animal models using similar approaches to manipulate NAA levels, indicating a promising avenue for human treatment.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Pleasure, David E. — University of California at Davis
- Study coordinator: Pleasure, David E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.